Pamicell Signs Collaboration Agreement with ST Pharm to Supply mPEG for mRNA Vaccine LNP Manufacturing

[Asia Economy Reporter Hyungsoo Park] Pharmicell announced on the 17th that it has signed a joint cooperation business agreement with ST Pharm for the supply of mPEG.

According to the contract, Pharmicell will exclusively supply three types of mPEG derivatives (2K) and raw materials for mRNA vaccine manufacturing to ST Pharm domestically. ST Pharm, participating in the K-mRNA consortium, plans to use these products in the lipid nanoparticle (LNP) technology of mRNA vaccines.

LNP is a technology used for delivering mRNA vaccine substances into the human body, and the mPEG (2K) produced by Pharmicell is used for this purpose. Lipid nanoparticles containing mPEG (2K) help easily pass through cell membranes and remain stable in the body for an extended period.

A Pharmicell official stated, “Due to the characteristics of LNP technology, it is difficult to change the materials used during development to other substances, so Pharmicell’s products are expected to be continuously used.”

He added, “We are also supplying mPEG for mRNA vaccines to the German company Merck,” and “Since the use of mPEG is essential for COVID-19 mRNA vaccines, supply requests from global companies both domestically and internationally continue, so demand is expected to steadily increase.”

Pharmicell is participating in a vaccine company council composed of the government and domestic pharmaceutical and bio companies. The vaccine company council was launched with the goal of expanding global vaccine supply by utilizing domestic vaccine production capabilities and advancing into a global vaccine hub.

This content was produced with the assistance of AI translation services.